In humans, mutations in the ortholog of HOE-1, ELAC2, are associated with both hypertrophic cardiomyopathy (Haack et al., 2013; Shinwari et al., 2017; Saoura et al., 2019) and prostate cancer (Tavtigian et al., 2001; Korver et al., 2003; Noda et al., 2006). Here, ELAC2 is linked to hypertrophic cardiomyopathy.